Dr. Allen Seftel, a Urologist from the Cooper University Hospital in Camden, NJ, and colleagues provide an update in the August 2015 issue of Mayo Clinic Proceedings, for clinicians treating hypogonadal men, where they looked at the most recent Endocrine Society guidelines from 2010 and note where changes could be made or where evidence neither supports or denies efficacy and safety of testosterone therapy. Notably, patients with frailty and metabolic syndrome are two instances where changes are recommended. No Level 1 evidence was found to suggest that TRT is associated with CV disease. Available at: [ Ссылка ]

свернуть